Aminophylline 250mg Fresenius Injection
PDF Leaflet Revision Date: 22 June 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Second line treatment of acute and chronic bronchial obstruction.
Dosage (summary)
Loading: 6 mg/kg lean body mass IV; Maintenance: 0.4-0.5 mg/kg/hour for non-smokers.
Special Populations
- Elderly
- Hepatic impairment
- Renal impairment
- Congestive cardiac failure
Pregnancy & Breastfeeding
Safety not established; monitor neonates for apnoea and irritability.
Key Drug Interactions
- Fluvoxamine may increase theophylline levels.
- Smoking increases theophylline clearance.
- Cimetidine may raise theophylline levels.
Contraindications
- Hypersensitivity to aminophylline or xanthines.
- Porphyria.
- Active gastritis or peptic ulcer disease.
Common side effects
- Nausea
- Vomiting
- Headache
- Tachycardia
- Dizziness
Counselling Points
- Avoid rapid IV injection.
- Monitor for signs of toxicity.
- Do not alter dose without consulting a doctor.
Serious warnings
- Narrow therapeutic index; monitor serum levels.
- Risk of CNS and cardiovascular side effects.
Important Disclaimer
The Aminophylline 250mg Fresenius Injection professional information leaflet below is the property of Fresenius Kabi Manufacturing Sa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
